HC Wainwright Has Negative View of MediWound FY2024 Earnings
Analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of MediWound in a report released on Wednesday, ...
HC Wainwright Cuts Alector (NASDAQ:ALEC) Price Target to $7.00
Alector (NASDAQ:ALEC – Free Report) had its price target reduced by HC Wainwright from $35.00 to $7.00 in a report published on Friday, MarketBeat.com reports. They currently have a buy rating on the ...
Fintel on MSN7d
HC Wainwright & Co. Downgrades Mainz Biomed N.V. (MYNZ)
Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...
Fintel on MSN6d
HC Wainwright & Co. Initiates Coverage of Sarepta Therapeutics (SRPT) with Sell Recommendation
Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with ...
Looking At Cipher Mining's Recent Unusual Options Activity
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...
Yahoo Finance3d
Co-Diagnostics, Inc. (CODX)
Reiterates HC Wainwright & Co.: Neutral to Neutral 11/11/2024 Maintains HC Wainwright & Co.: Neutral to Neutral 8/12/2024 Reiterates HC Wainwright & Co.: Neutral to Neutral 6/17/2024 Maintains HC ...
Nasdaq11d
HC Wainwright & Co. Initiates Coverage of Sarepta Therapeutics (LSE:0L35) with Sell Recommendation
Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...
Nasdaq11d
HC Wainwright & Co. Initiates Coverage of Sarepta Therapeutics (SRPT) with Sell Recommendation
Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sell recommendation. As of November 21, 2024, the average one-year ...